1DELCHIER J G, COHEN G, HUMPHRIES T J. Rabeprazole, 20 mg once daily or 10 mg twice daily, in the healing of erosive gastrooesphageal reflux disease[J]. Scand J Gastroenterol, 2000, 35(12): 1 245-1 250.
2MIWA H, YAMADA T, SATO K. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole[J]. Dig Dis Sci, 2000, 45(1): 77-82.
3TSUTSUI N, TANEIKE I, OHARA T, et al. A novel action of the proton pump inhibitor Rabeprazole and its thioether derinative against the motility of Helicobacter pylory[J]. Antimicrob Agents Chemother, 2000, 44(11): 3 069-3 073.
4HIZAWA K, NAKAHARA J, YANO Y, et al. Effect of amixicillin, clarithromycin and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection[J]. J Clin Gastroenterol, 2000, 31(4): 338-339.
5NISHINA K, MIKAWA K, TAKAO I, et al. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery[J]. Anesth Analg, 2000, 90(3): 717-721.
6DEKKERS C P, BEKER J A, THJODLEIFESSON B, et al. Double-blind comparison [correction of double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 1999, 13(1): 49-57.
7KEANE W F, SWAN S K, GRIMES I, et al. Rabeprazole: pharmacokinetics and tolerability in patients with stable,end-stage renal failure[J]. J Clin Pharmacol, 1999, 39(9): 927-933.
8DAMMANN H G,BURHARDT F, WOLF N. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers[J]. Aliment Pharmacol Ther, 1999, 13(9): 1 195-1 203.
9HONGO M, KIMPARA T, MORIYAMA S, et al. Effect of rabeprazole (E3810), a novel proton pump inhibitor, on intragastric pH in healthy volunteers[J]. Tohoku J Exp Med, 1998, 186(1): 43-50.
10LANGTRY H D, MARKHAM A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders[J]. Drugs, 1999, 58(4): 725-742.
